Shorted

Orthocell (OCC) News

Latest articles and price-sensitive announcements with AI sentiment classification.

Kalkine
Neutral
just now

Why Does Orthocell (ASX:OCC) Matter Now Among ASX Healthcare Stocks?

Highlights Orthocell is in focus after a fresh company disclosure added new context to the public record. The healthcare stocks lens centres on clinical progress, regulatory pathways, commercial execution and funding discipline. The broader Australian market backdrop remains important when reading company-specific developments. Australian shares are being assessed against a shifting mix of company updates, sector conditions and global market signals, making fresh disclosures especially import...

Continue reading
Kalkine
Neutral
just now

Why Is Regenerative medicine group Orthocell (ASX:OCC) Turning Heads Right Now?

Highlights Commercial momentum in regenerative medicine and a fresh patent win kept ASX small-cap healthcare in focus this week. Orthocell and Recce Pharmaceuticals show how milestones can reshape the story for emerging medical names. Market participants are watching revenue traction, regulatory progress and intellectual property across the two companies. Regenerative medicine group Orthocell (ASX:OCC), a West Australian developer of nerve-repair and tissue-regeneration products, stood out acro...

Continue reading
Kalkine
Neutral
just now

Orthocell Limited Issues 62,894 Shares to Directors Under Employee Awards Plan, Boosting Total Share Capital

Orthocell Limited (ASX: OCC) has applied for quotation of 62,894 ordinary fully paid shares issued to its directors on 17 July 2026 as part of director fee compensation under the company's Employee Awards Plan. These shares were issued at AUD 0.75610000 each and had prior shareholder approval at the 2025 annual general meeting. Upon quotation, Orthocell's total issued ordinary fully paid share capital will increase to 272,316,531 shares on the ASX. Key Points Orthocell Limited (OCC) issued 62...

Continue reading
Kalkine
Neutral
just now

Orthocell Grants 263,895 Retention Rights and 99,264 Performance Rights to Employees Under Employee Awards Plan

On 17 July 2026, Orthocell Limited (ASX: OCC) issued a total of 363,159 unquoted employee incentive securities, consisting of 263,895 retention rights and 99,264 performance rights. These grants were made under the company’s Employee Awards Plan and did not require shareholder approval pursuant to ASX Listing Rule 7.2 exception 13. This latest equity allocation reflects Orthocell’s ongoing commitment to align employee incentives with long-term shareholder value creation within the biomedical...

Continue reading
Kalkine
Neutral
just now

Why Is Regenerative medicine group Orthocell (ASX:OCC) Turning Heads Right Now?

Highlights Commercial momentum in regenerative medicine and a fresh patent win kept ASX small-cap healthcare in focus this week. Orthocell and Recce Pharmaceuticals show how milestones can reshape the story for emerging medical names. Market participants are watching revenue traction, regulatory progress and intellectual property across the two companies. Regenerative medicine group Orthocell (ASX:OCC), a West Australian developer of nerve-repair and tissue-regeneration products, stood out acro...

Continue reading
Kalkine
Neutral
just now

Orthocell (ASX:OCC) Expands Global Reach With Strong Revenue Momentum

Highlights Record annual revenue reflects expanding commercial footprint. Remplir adoption continues to grow across key international markets. Strong financial position supports global expansion strategy. Orthocell continues to strengthen its position in regenerative medicine through growing demand for its flagship products, expanding international market access, increasing hospital adoption, and advancing regulatory milestones across multiple regions. ...

Continue reading
Kalkine
Neutral
just now

Why Is Orthocell (ASX:OCC) in Focus Over Its Cash Position?

Highlights Orthocell continues maintaining a debt-free balance sheet while advancing regenerative medicine programs. Growing revenue and available cash resources are supporting the company's commercial expansion strategy. Regulatory progress and product commercialisation remain key drivers for the healthcare company. Orthocell Ltd (ASX:OCC) has attracted renewed market attention as its financial position continues supporting the commercial expansion of its regenerativ...

Continue reading
Kalkine
Neutral
just now

Is Orthocell (ASX:OCC) Expanding Its Role in ASX All Ordinaries Biotech Sector?

Highlights Orthocell completes first Remplir procedure in US military hospital network. Healthcare sector activity reflects medical technology adoption and expansion. Market participation highlights integration of biotech companies within ASX indices. Orthocell completes a Remplir procedure in a US military hospital network, highlighting clinical deployment and biotechnology sector participation within ASX All Ordinaries. The healthcare and biotechnology sector represents a significant ...

Continue reading
Kalkine
Neutral
just now

How Orthocell Limited (ASX:OCC) Fits in ASX 300 Healthcare Sector Trends

Highlights Orthocell prepares to release quarterly update and host investor webinar. Biotechnology operations reflect ongoing clinical and commercial activity. Healthcare sector participation continues across Australian equity indices. Orthocell prepares quarterly update and investor webinar, reflecting healthcare sector activity and biotechnology development within Australian equity markets. The healthcare and biotechnology sector remains a key contributor to Australian equity markets,...

Continue reading
Kalkine
Neutral
just now

Orthocell Advances Global Reach with Remplir Success

Highlights Remplir used in real-world surgical settings Global expansion strategy gaining traction Strong financial base supports ongoing growth Orthocell’s Remplir device gains real-world validation through surgical use in demanding environments, strengthening its global expansion strategy and reinforcing its presence across medical and defence-related applications. Orthocell’s Remplir nerve repair device has taken a significant step forward, with its successful application...

Continue reading